Breast Imaging

What Imaging Is Best for Male Breast Cancer Screening in High-Risk Patients?

·
What Imaging Is Best for Male Breast Cancer Screening in High-Risk Patients?

A 58-year-old male presents for his annual physical. He is asymptomatic but expresses concern about his breast cancer risk, noting his mother and a paternal aunt both had the disease. Genetic testing years ago confirmed he carries a pathogenic BRCA2 variant. You recognize he falls into a higher-than-average risk category and that clinical guidelines now support initiating surveillance. The immediate question is which imaging modality is the most appropriate first step for screening in this specific clinical context. According to the American College of Radiology (ACR) Appropriateness Criteria, for an adult male with higher-than-average risk, Digital Breast Tomosynthesis screening is rated Usually Appropriate.

Who Qualifies as a ‘Higher-Than-Average Risk’ Male for Breast Cancer Screening?

This clinical workflow applies specifically to adult men who have risk factors that place them at a significantly higher lifetime risk of developing breast cancer compared to the general male population. Identifying these individuals is the crucial first step before considering screening. Key inclusion criteria for this scenario include:

  • Known pathogenic genetic mutations: Carriers of mutations in genes such as BRCA1, BRCA2, PALB2, CHEK2, and ATM have a substantially elevated risk.
  • Strong family history: A significant history of breast, ovarian, pancreatic, or prostate cancer in first-degree relatives (parents, siblings, children) or multiple second-degree relatives.
  • Personal history of chest wall radiation: Particularly radiation received between the ages of 10 and 30, often for treatment of conditions like Hodgkin lymphoma.
  • Certain medical conditions: Conditions associated with altered estrogen-to-androgen ratios, such as Klinefelter syndrome, or significant liver disease like cirrhosis.

This guidance is distinct from other clinical situations. It does not apply to average-risk men with no specific risk factors, for whom routine screening is not currently recommended. It also does not apply to men younger than 25, regardless of risk, as the risk-benefit balance of imaging is different in that age group and requires separate consideration.

What Diagnoses Are You Working Up in This Scenario?

The primary goal of screening is to detect malignancy at an early, non-palpable, and more treatable stage. The differential diagnosis in this screening context is focused on identifying preclinical breast cancer while being aware of the benign entities that can be incidentally found.

Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer in men, accounting for the vast majority of cases. Screening aims to detect IDC as a small mass or architectural distortion before it becomes clinically apparent or metastasizes. In men, these cancers are often located subareolarly.

Ductal Carcinoma in Situ (DCIS): A non-invasive form of breast cancer where abnormal cells are confined to the milk ducts. Detecting DCIS is a key objective of screening, as it can be a precursor to invasive cancer. On mammography, it often presents as microcalcifications.

Benign Conditions: While not the target of screening, imaging will often visualize benign findings. The most common is gynecomastia, the benign proliferation of glandular breast tissue. It’s important to differentiate its typical appearance (flame-shaped, retroareolar density) from a suspicious mass. Other benign findings like lipomas or cysts may also be seen but are not the primary focus of a screening workup.

Why Is Digital Breast Tomosynthesis the Recommended Study for This Presentation?

For high-risk male patients, both standard two-dimensional (2D) Mammography screening and Digital Breast Tomosynthesis (DBT, or “3D mammography”) are rated as Usually Appropriate by the ACR. However, DBT is often favored in practice and is listed as the top recommended procedure for its distinct advantages in this population.

DBT acquires multiple low-dose images of the breast from different angles, which are then reconstructed into a three-dimensional dataset. This technique helps to minimize the effect of overlapping breast tissue, a common issue that can obscure cancers on standard 2D mammograms. In the male breast, which is typically smaller and can have dense glandular tissue from gynecomastia, DBT’s ability to “scroll through” the tissue can improve the visualization of subtle masses or architectural distortions. This can lead to higher cancer detection rates and may reduce the number of patients called back for additional imaging due to false positives.

Several alternative imaging modalities are rated as Usually not appropriate for initial screening in this scenario, for clear reasons:

  • MRI breast without and with IV contrast: While a primary screening tool for high-risk women, its role in men is less established. The much lower incidence of breast cancer in men, even high-risk men, changes the risk-benefit calculation. The high sensitivity of MRI can lead to a significant number of false-positive findings, potentially resulting in unnecessary biopsies and patient anxiety, without a proven mortality benefit in this population.
  • US breast (Ultrasound): Ultrasound is an excellent tool for diagnostic evaluation of a palpable lump or a finding seen on a mammogram. However, as a primary screening tool, it is operator-dependent, has lower sensitivity for detecting microcalcifications (a key sign of DCIS), and has not been shown to be effective for screening the entire breast in asymptomatic individuals.

The radiation dose for both mammography and DBT is low (ACR Relative Radiation Level ☢☢, corresponding to 0.1-1 mSv), and the benefits of early detection in this high-risk group are considered to outweigh the small radiation risk. For detailed technical specifications on image acquisition, refer to a standard Screening Mammography (with DBT) protocol.

What’s Next After Digital Breast Tomosynthesis Screening? Downstream Workflow

The results of the screening DBT, reported using the Breast Imaging Reporting and Data System (BI-RADS) classification, will dictate the next steps in the clinical workflow.

If the result is negative (BI-RADS 1 or 2): A finding of “Negative” or “Benign” means no evidence of malignancy was found. The patient should be counseled to continue with routine annual screening and to remain aware of any new symptoms, such as a palpable lump, skin changes, or nipple discharge, which would warrant a prompt diagnostic evaluation.

If the result is incomplete (BI-RADS 0): This indicates that the initial screening images are insufficient for a final assessment. The patient must be recalled for additional imaging. This typically involves diagnostic mammography, which may include spot compression or magnification views to better characterize an area of concern, and often a targeted breast ultrasound.

If the result is suspicious (BI-RADS 4 or 5): A finding that is “Suspicious” or “Highly Suggestive of Malignancy” requires tissue sampling for a definitive diagnosis. The patient should be referred promptly for a biopsy, which is most commonly performed under ultrasound or stereotactic (mammographic) guidance. A referral to a breast surgeon or specialist is appropriate at this stage for consultation and management planning.

Pitfalls to Avoid (and When to Get Help)

Navigating male breast cancer screening requires avoiding several common pitfalls to ensure timely and accurate diagnosis.

  • Underestimating risk: Failing to take a comprehensive personal and family history can lead to missing the opportunity to screen a high-risk individual. Always ask about cancer history in both male and female first- and second-degree relatives.
  • Dismissing a palpable lump: If a patient presents with a palpable breast lump, this is a diagnostic, not a screening, scenario. Do not order a “screening mammogram.” The order should be for a diagnostic mammogram and ultrasound, and the patient requires an urgent referral.
  • Misinterpreting gynecomastia: While most retroareolar tissue in men is benign gynecomastia, any eccentric, unilateral, or suspicious-appearing density should be worked up further. Do not assume all male breast tissue is benign.
  • Using the wrong screening tool: Avoid ordering ultrasound or MRI as the initial screening test. Adhering to the ACR guidelines ensures the most evidence-based approach is used first.

If there is any clinical or imaging uncertainty, or if a biopsy is warranted, immediate escalation to a breast imaging radiologist and a breast surgeon is the standard of care.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to male breast cancer imaging, and for tools to assist in ordering and patient communication, the following GigHz resources are available:

Frequently Asked Questions

At what age should screening begin for a high-risk male patient?

There is no universal consensus, but many guidelines suggest initiating screening around age 35-40, or 10 years earlier than the youngest age of breast cancer diagnosis in the family. This decision should be made in consultation with the patient and potentially a genetics counselor.

Is a screening mammogram for a man different than for a woman?

The technique is fundamentally the same, involving compression and standard views (CC and MLO). However, positioning can be more challenging due to less breast tissue and the presence of pectoral muscle. Technologists experienced in male mammography are crucial for obtaining high-quality images.

If a high-risk man has dense breast tissue or gynecomastia, should I order an ultrasound in addition to the mammogram for screening?

No, according to the ACR Appropriateness Criteria, ultrasound is ‘Usually not appropriate’ as a primary or supplemental screening tool for asymptomatic high-risk men. Its role is reserved for diagnostic workup of a clinical or mammographic finding. Digital Breast Tomosynthesis (DBT) is the preferred method for dealing with tissue density.

Why isn’t MRI recommended for screening high-risk men when it’s standard for high-risk women?

The recommendation is based on the balance of risks and benefits. While breast cancer risk is elevated in this male population, the absolute incidence is still far lower than in high-risk women. The high sensitivity of MRI would likely lead to a large number of false positives and unnecessary biopsies, without sufficient evidence of a mortality benefit to justify its use as a routine screening tool in men.

Does insurance typically cover screening mammography for high-risk men?

Coverage can vary by plan and jurisdiction. However, with growing awareness and guideline support, coverage is becoming more common, especially with clear documentation of the patient’s high-risk status (e.g., genetic test results, detailed family history). It is often necessary to provide this documentation with the imaging order.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026